6.2 Antihypertensives & Guideline-Directed Heart Failure Therapies

6.2 Antihypertensives & Guideline-Directed Heart Failure Therapies

[!NOTE] Clinical Blueprint Alignment: The American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) guidelines establish four foundational pharmacologic pillars for Heart Failure with Reduced Ejection Fraction (HFrEF). Mastery of dosing, contraindications, adverse effects, and laboratory thresholds across these pillars is essential for ANCC CV-BC certification.

Heart failure pharmacotherapy has evolved from symptom alleviation with diuretics and digoxin to neurohormonal disease modification that reverses adverse ventricular remodeling, preserves renal hemodynamics, and significantly lowers all-cause mortality.

---

The Four Pillars of Guideline-Directed Medical Therapy (GDMT) in HFrEF

For all patients with symptomatic chronic HFrEF (Stage C, NYHA Class II–IV, Left Ventricular Ejection Fraction $\text{LVEF} \le 40%$) without contraindications, guidelines mandate simultaneous or rapid sequential initiation of the 'Four Pillars' of GDMT. Each pillar exerts independent and additive reductions in cardiovascular mortality and heart failure hospitalizations.

                    ┌───> Pillar 1: ARNI (Sacubitril/Valsartan) [Preferred over ACEi/ARB]
                    │
Foundational GDMT   ├───> Pillar 2: Evidence-Based Beta-Blocker (Carvedilol / Metoprolol Succinate / Bisoprolol)
for HFrEF           │
(LVEF <= 40%)       ├───> Pillar 3: Mineralocorticoid Receptor Antagonist (Spironolactone / Eplerenone)
                    │
                    └───> Pillar 4: SGLT2 Inhibitor (Dapagliflozin / Empagliflozin)

Pillar 1: Renin-Angiotensin System Inhibition (ARNI / ACEi / ARB)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/Valsartan (Entresto)

• Mechanisms: Combines a neprilysin inhibitor prodrug (sacubitril) with an angiotensin II receptor blocker (valsartan).
  • Neprilysin Inhibition: Neprilysin is a neutral endopeptidase responsible for degrading endogenous vasoactive peptides, including Atrial Natriuretic Peptide (ANP), B-type Natriuretic Peptide (BNP), bradykinin, and adrenomedullin. By inhibiting neprilysin, sacubitril enhances natriuresis, diuresis, systemic vasodilation, and anti-fibrotic signaling.
  • AT1 Receptor Blockade: Concurrently blocks the angiotensin II type-1 ($AT_1$) receptor, suppressing vasoconstriction, aldosterone secretion, and sympathetic activation without allowing unopposed angiotensin II accumulation.
• Clinical Efficacy: The landmark PARADIGM-HF trial demonstrated a 20% reduction in cardiovascular death or heart failure hospitalization compared to enalapril. ARNI therapy is designated a Class 1A recommendation as the preferred first-line agent over ACE inhibitors or ARBs for HFrEF.

[!CAUTION] The Mandatory 36-Hour Washout Rule: Both angiotensin-converting enzyme (ACE) and neprilysin degrade bradykinin. Co-administration of an ACE inhibitor with an ARNI leads to massive, unregulated accumulation of bradykinin, precipitating life-threatening severe angioedema. A strict 36-hour washout period is legally and clinically required between the last dose of an ACE inhibitor (e.g., lisinopril, enalapril) and the initiation of sacubitril/valsartan. In contrast, no washout period is required when switching from an ARB to an ARNI.

ACE Inhibitors & Angiotensin Receptor Blockers (ARBs)

• ACE Inhibitors (Lisinopril, Enalapril, Ramipril): Inhibit the conversion of angiotensin I to angiotensin II, decreasing afterload ($SVR$), lowering aldosterone production, and decreasing myocyte apoptosis. Indicated in patients unable to tolerate an ARNI due to financial, insurance, or clinical constraints.
  • Adverse Effects: Persistent dry hacking cough (seen in 10% to 20% of patients due to bradykinin and substance P accumulation in pulmonary airways), hyperkalemia, acute kidney injury, and angioedema.
• ARBs (Losartan, Valsartan, Candesartan): Selectively displace angiotensin II from $AT_1$ receptors. Indicated for patients who develop an intolerable ACE-inhibitor-induced dry cough. They do not increase bradykinin, substantially reducing cough incidence.
• Laboratory Monitoring & Renal Parameters:
  • Assess serum creatinine and potassium at baseline, within 1 to 2 weeks of initiation, and after any dose titration.
  • A transient rise in serum creatinine of up to 30% above baseline is hemodynamically expected and acceptable, reflecting reduced intraglomerular hyperfiltration. Therapy should not be discontinued unless hyperkalemia ($K^+ > 5.5\text{ mEq/L}$) or symptomatic azotemia ensues.

---

Pillar 2: Evidence-Based Beta-Blockers

Only three specific beta-blockers are clinically proven to reduce all-cause mortality, prevent sudden cardiac arrest, and induce reverse LV remodeling in chronic HFrEF:

1. Carvedilol (Coreg): Non-selective $\beta_1/\beta_2$-adrenergic blocker with additional $\alpha_1$-adrenergic antagonism (promoting peripheral vasodilation and afterload reduction). Administer with food to slow absorption and minimize orthostatic dizziness.
2. Metoprolol Succinate (Toprol-XL): Cardioselective $\beta_1$-adrenergic blocker formulated as an extended-release once-daily tablet. (Clinical Trap: Metoprolol Tartrate [Lopressor] is short-acting and lacked mortality reduction in clinical heart failure trials!).
3. Bisoprolol (Zebeta): Highly cardioselective $\beta_1$-adrenergic blocker once daily.

Initiation, Titration & Clinical Rules

• Euvolemic Requirement: Initiate beta-blockers ONLY when the patient is clinically stable and euvolemic (free of overt pulmonary edema, severe peripheral congestion, or inotrope dependence). Initiating in an acutely decompensated, wet patient can precipitate acute cardiogenic collapse due to sudden negative inotropy.
• 'Start Low, Go Slow': Double the dose every 2 to 4 weeks while monitoring resting heart rate (target 55–65 bpm), blood pressure, and signs of fluid retention.
• Patient Counseling on Transient Fatigue: Inform patients that transient fatigue and mild fluid accumulation may occur during early initiation; emphasize that this does not indicate drug failure and will resolve. Temporary increases in loop diuretics manage fluid retention.
• Never Abruptly Discontinue: Abrupt cessation triggers severe rebound adrenergic storm, marked reflex tachycardia, hypertensive crisis, acute myocardial ischemia, and fatal ventricular arrhythmias. If a patient is admitted with mild to moderate decompensated heart failure, maintain their baseline beta-blocker dose unless they are in cardiogenic shock or profound bradycardia.

---

Pillar 3: Mineralocorticoid Receptor Antagonists (MRAs)

• Agents: Spironolactone (Aldactone) and Eplerenone (Inspra).
• Mechanism: Competitively antagonize aldosterone at intracellular mineralocorticoid receptors in the renal distal convoluted tubule and collecting duct. In addition to mild natriuresis, they inhibit aldosterone-mediated myocardial interstitial fibrosis, ventricular collagen deposition, and vascular stiffness.
• Mortality Proof: RALES and EPHESUS trials established a 30% reduction in all-cause mortality and sudden cardiac death in HFrEF.
• Mandatory Safety Thresholds Prior to Initiation:
  • Baseline serum potassium must be $\le 5.0\text{ mEq/L}$.
  • Baseline eGFR must be $\ge 30\text{ mL/min/1.73m}^2$ (or serum creatinine $\le 2.5\text{ mg/dL}$ in men, $\le 2.0\text{ mg/dL}$ in women).
• Monitoring Protocol: Check serum potassium and renal function at 1 week, 4 weeks, and every 3 to 6 months thereafter. If potassium exceeds $5.5\text{ mEq/L}$, decrease dose by 50%; if potassium reaches $\ge 6.0\text{ mEq/L}$, discontinue immediately.
• Endocrine Adverse Effects: Spironolactone non-selectively binds androgen and progesterone receptors, causing painful gynecomastia, breast tenderness, and erectile dysfunction in up to 10% of men. If this occurs, switch the patient to eplerenone, a highly selective mineralocorticoid antagonist with negligible androgen receptor affinity.

---

Pillar 4: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

• Agents: Dapagliflozin (Farxiga, 10 mg daily) and Empagliflozin (Jardiance, 10 mg daily).
• Mechanism: Inhibit SGLT2 cotransporters in the renal proximal convoluted tubule, blocking glucose and sodium reabsorption. Induces osmotic diuresis, reduces cardiac preload and afterload, improves myocardial cellular energetics, reduces intraglomerular pressure, and attenuates cardiac fibrosis.
• Broad Clinical Indication: Clinical trials (DAPA-HF, EMPEROR-Reduced, DELIVER, EMPEROR-Preserved) proved that SGLT2 inhibitors significantly reduce cardiovascular death and heart failure hospitalizations across the entire spectrum of ejection fractions (both HFrEF and HFpEF / HFmrEF). Efficacy is independent of whether the patient has type 2 diabetes mellitus.
• Administration Advantage: Fixed once-daily oral dosing (10 mg daily) requiring no dose titration.
• Adverse Effects & Nursing Vigilance:
  • Genital Mycotic Infections: Candidiasis and urinary tract infections; educate patients on meticulous personal hygiene.
  • Hypovolemia / Hypotension: Mild osmotic diuresis may require slight down-titration of loop diuretics.
  • Euglycemic Diabetic Ketoacidosis (euDKA): Rare but life-threatening complication occurring in diabetic patients. Characterized by severe metabolic ketoacidosis (elevated anion gap, serum ketones, tachypnea, nausea, fatigue) with normal or only mildly elevated blood glucose ($< 250\text{ mg/dL}$). SGLT2 inhibitors must be withheld at least 3 to 4 days prior to scheduled elective surgery or during severe acute medical illness.

---

Additional Guideline-Directed Heart Failure Therapies

---

Antihypertensive Classes in Cardiovascular Practice

Thiazide & Thiazide-Like Diuretics

• Agents: Chlorthalidone (12.5 to 25 mg daily) and Hydrochlorothiazide (HCTZ, 25 to 50 mg daily).
• Mechanism: Inhibit the $Na^+/Cl^-$ cotransporter in the distal convoluted tubule, promoting renal excretion of sodium, chloride, and water.
• Clinical Differentiation: Chlorthalidone has a significantly longer half-life (40–60 hours vs. 6–12 hours for HCTZ) and superior cardiovascular morbidity and stroke reduction in landmark trials (ALLHAT). It is the guideline-preferred thiazide.
• Metabolic Complications: Hypokalemia, hyponatremia, hypomagnesemia, hyperuricemia (precipitating acute gouty arthritis), hyperglycemia, and hypercalcemia.
• Renal Cutoff: Ineffective as monotherapy when eGFR falls below $30\text{ mL/min/1.73m}^2$; patients with advanced renal dysfunction require loop diuretics (furosemide, torsemide, bumetanide).

Calcium Channel Blockers (CCBs): Dihydropyridine vs. Non-Dihydropyridine

                                  ┌───> Dihydropyridines (Amlodipine, Nifedipine, Nicardipine)
                                  │     - Selective Arteriolar Vasodilation
                                  │     - Safe in HFrEF (Amlodipine)
Calcium Channel Blockers (CCBs) ──┤     - Primary Side Effect: Dependent Peripheral Ankle Edema
                                  │
                                  └───> Non-Dihydropyridines (Diltiazem, Verapamil)
                                        - SA & AV Node Conduction Depression + Negative Inotropy
                                        - CONTRAINDICATED in HFrEF (Precipitates Cardiogenic Decompensation)
                                        - Primary Use: Rate Control in Atrial Arrhythmias

1. Dihydropyridine CCBs (Amlodipine, Nifedipine, Nicardipine)

• Action: High selectivity for vascular smooth muscle L-type calcium channels, causing potent arteriolar vasodilation with minimal cardiac electrophysiologic or contractility effects.
• Clinical Indications: First-line monotherapy for hypertension, particularly in older adults and self-identified Black patients; highly effective for isolated systolic hypertension and angina.
• HFrEF Safety: Amlodipine does not depress left ventricular ejection fraction or worsen mortality in HFrEF; it can be safely added if additional blood pressure control is required on top of GDMT.
• Dependent Peripheral Edema: Causes dose-dependent bilateral ankle edema via selective precapillary arteriolar dilation (transudative fluid shift), NOT fluid retention. It does not respond to diuretic therapy; management involves dose reduction or adding an ACEi/ARB (which dilates post-capillary venules, balancing capillary hydrostatic pressures).

2. Non-Dihydropyridine CCBs (Diltiazem, Verapamil)

• Action: Inhibit L-type calcium channels in both vascular smooth muscle and myocardial cells, with pronounced effects on the sinoatrial and atrioventricular nodes.
• Hemodynamic Effects: Potent negative inotropy (contractility depression), negative chronotropy (heart rate reduction), and negative dromotropy (AV nodal conduction delay).
• Primary Indications: Ventricular rate control in atrial fibrillation or atrial flutter; management of paroxysmal supraventricular tachycardia; stable chronic angina.
• Strict Contraindication in HFrEF: Non-dihydropyridine CCBs are absolutely contraindicated in patients with HFrEF ($\text{LVEF} \le 40%$). Their potent negative inotropic properties cause acute left ventricular pump failure, cardiogenic pulmonary edema, and increased cardiovascular mortality.